Cure For Ibd
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2016 | 146,027 | 99,650 | 46,377 | 6.4 | — |
| 2017 | 330,550 | 225,661 | 104,889 | 8.4 | 0% |
| 2018 | 803,532 | 754,507 | 49,025 | 3.3 | 0% |
| 2019 | 337,018 | 453,689 | −116,671 | 2.9 | 0% |
| 2020 | 199,382 | 224,699 | −25,317 | 4.5 | 0% |
| 2021 | 178,562 | 158,063 | 20,499 | 8.0 | 0% |
| 2022 | 103,462 | 76,938 | 26,524 | 20.5 | 0% |
| 2023 | 47,640 | 89,368 | −41,728 | 12.0 | 0% |
In its most recent public year (2023), this organization spent $41,728 more than it brought in. Its reserves stood at about 12 months of spending, up from 6.4 in 2016. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Cure For Ibd's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works